How to Approach Onto Innovation Stock Ahead of Q3 Earnings?

Ahead of its Nov. 9 Q3 report, Onto Innovation expects revenue of $380–$400 million and non-GAAP EPS of $2.18–$2.38; consensus is $390.7 million and $2.27, respectively. Growth drivers include a record backlog above $1.1 billion, a raised 2026 advanced-packaging growth outlook of about 80% from 50%, and Q2 Dragonfly inspection growth of 30% sequentially, offset by customer concentration and cost risks. Shares fell 48.8% in the past month, while the company’s Earnings ESP is 0.00% and the article’s model does not predict an earnings beat.

Analysis

The key question is not whether AI-related demand exists, but whether the recent selloff has reset expectations enough to compensate for ONTO’s unusually concentrated conversion risk. Backlog is not revenue: the large Dragonfly order from one OSAT partner is weighted to 2027, leaving qualification, delivery timing and customer capex as the bridge investors must underwrite. A delay could expose how much of the growth narrative is dependent on a small number of buyers, even if broader AI spending remains intact.

The sharp decline across the named inspection peers suggests a sector de-rating is part of the move; ONTO’s larger fall versus KLAC, CAMT and NVMI also leaves room for company-specific execution or positioning concerns. A Q3 beat alone may not reverse that. The more durable catalyst is evidence that sequential growth converts to cash and margins while material/freight costs, Semilab losses and customer concentration remain contained. The Rigaku minority investment is a longer-dated product-development option, not a near-term earnings engine; fair-value accounting can add reported volatility without equivalent operating progress.

For the next few sessions, event risk dominates: the stated consensus is close to company guidance, and the article’s zero Earnings ESP offers no independent beat signal. Over 1–3 months, shipment cadence, backlog quality and margin delivery matter more than headline growth. Over 6–18 months, advanced packaging and HBM exposure can support upside, but a pause in a few customers’ capex or regional disruption could reverse it. The reported forward P/E comparison is not enough to establish cheapness without checking the earnings base and current estimates.

Key Decisions for Investors

• Avoid adding ONTO immediately ahead of the Nov. 9 after-close report; treat the event as binary and do not infer a valuation floor from the drawdown alone.
• For investors seeking exposure, stage a post-earnings long only if guidance supports continued sequential growth and gross-margin expansion, with confirmation that backlog is converting rather than merely accumulating. Reassess or exit if guidance weakens, margin expansion stalls, or the large OSAT deliveries are delayed.
• A conditional relative-value setup is long ONTO versus short CAMT after results only if ONTO demonstrates better order conversion and execution; keep sizing modest because both positions retain semiconductor-capex and risk-off exposure. The thesis fails if ONTO’s relative performance does not improve alongside stronger company-specific metrics.
• Before using options, check the implied move and event volatility; absent that pricing, there is no demonstrated risk/reward advantage to paying for a pre-earnings straddle.